Cardiff Oncology Inc

NASDAQ CRDF
$2.17 0.04 1.88%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 17.5 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
208.89M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
185.51M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
66.52M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-50.00 %

Upcoming events Cardiff Oncology Inc

All events
No upcoming events scheduled

Stock chart Cardiff Oncology Inc

Stock analysis Cardiff Oncology Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-4.28 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
2.49 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-4.12 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.52 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-68.93 -50.00

Price change Cardiff Oncology Inc per year

1.95$ 5.35$
Min Max

Summary analysis Cardiff Oncology Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Cardiff Oncology Inc

Revenue and net income Cardiff Oncology Inc

All parameters

About company Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company's lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1 inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Address:
11055 Flintkote Avenue, San Diego, CA, United States, 92121
Company name: Cardiff Oncology Inc
Issuer ticker: CRDF
ISIN: US14147L1089
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2004-07-27
Sector: Healthcare
Industry: Biotechnology
Site: https://www.cardiffoncology.com